Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Long-Term Deferred Tax: 2023-2024

  • Ascendis Pharma A's Long-Term Deferred Tax fell 23.64% to -$7.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.8 million, marking a year-over-year decrease of 23.64%. This contributed to the annual value of -$7.9 million for FY2024, which is 25.23% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Long-Term Deferred Tax of -$7.8 million as of Q4 2024, which was down 23.64% from -$6.3 million recorded in Q4 2023.
  • Ascendis Pharma A's Long-Term Deferred Tax's 5-year high stood at -$6.3 million during Q4 2023, with a 5-year trough of -$7.8 million in Q4 2024.
  • Over the past 2 years, Ascendis Pharma A's median Long-Term Deferred Tax value was -$7.0 million (recorded in 2023), while the average stood at -$7.0 million.
  • Data for Ascendis Pharma A's Long-Term Deferred Tax shows a maximum YoY decreased of 23.64% (in 2024) over the last 5 years.
  • Ascendis Pharma A's Long-Term Deferred Tax (Quarterly) stood at -$6.3 million in 2023, then decreased by 23.64% to -$7.8 million in 2024.